Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ADMA Biologics Inc

ADMA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$9.47

▲ +0.64%

Market Cap $2.12B · Vol 487.72K

Key Metrics

P/E Ratio

13.43

FWD: 10.18

Market Cap

$2.12B

Mid Cap

Div Yield

N/A

EPS Growth

+30.00%

YoY

RSI (14)

65.18

Momentum

Beta

0.78

vs Market

52W High

$20.43

53.65% below

52W Low

$7.22

31.16% above

Volume

487.72K

Avg 1.09M

P/B

9.09

Price-to-book

ROE

N/A

Return on equity

Free Float

96.87%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ADMA Biologics Inc (ADMA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.34%

+6.76%

+11.41%

-41.14%

YTD

-48.08%

-44.20%

+108.59%

+535.57%

Financials & Valuation

TTM · Annual

Total Revenue	$510.17M
Net Income	$146.93M
Revenue Growth (YoY)	+1.98%
Gross Margin	57.36%
Operating Margin	37.53%
Net Profit Margin	28.80%
ROE	N/A
ROA · ROIC	32.82% · 31.45%

P/E Ratio	13.43
Forward P/E (FY1)	10.18
PEG Ratio	-1.16
P/S	8.76
P/B	9.09
P/FCF	162.41
EPS Growth	+30.00%
Outstanding Shares	223.98M

Technical Indicators

50-Day SMA	$8.79
200-Day SMA	$13.07
RSI (14)	65.18
Beta	0.78
52-Week High	$20.43
52-Week Low	$7.22

Volume Today	487.72K
Avg Daily Volume (30D)	1.09M
Relative Volume	0.45x
Volatility (10D)	52.29
Volatility (30D)	38.85
Free Float	96.87%

Analyst Consensus

BUY

Current Price $9.47

Mean Target $17.00

52W Low$7.22 52W High$20.43

Current

Target

$7.22 $20.43

Current Analyst target

+79.51% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG002NCK5N4

ISINUS0008991046

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.